📊 GOVX Key Takeaways
Is GeoVax Labs, Inc. (GOVX) a Good Investment?
GeoVax Labs is a development-stage biotech company with critically unsustainable financials: $21.5M annual operating losses against only $2.5M in revenue, supported by a dwindling cash reserve of $3.1M that provides less than 2 months of runway at current burn rates. The company faces imminent dilution risk and financing pressure with no evidence of near-term path to profitability or meaningful revenue generation.
GeoVax generates minimal revenue and posts extremely negative margins and returns, with operating cash burn far exceeding its cash balance. Despite being debt-free with a decent current ratio, the business appears reliant on external financing and uncertain pipeline progress, leaving fundamentals weak.
Why Buy GeoVax Labs, Inc. Stock? GOVX Key Strengths
- Zero debt burden eliminates leverage risk
- Positive stockholders equity of $3.8M remains on books
- Strong near-term current ratio of 2.74x provides immediate liquidity buffer
- Debt-free balance sheet
- Solid current/quick ratio supporting near-term liquidity
- Asset-light with minimal capex requirements
GOVX Stock Risks: GeoVax Labs, Inc. Investment Risks
- Catastrophic cash burn of $21.5M annually against $3.1M cash runway (approximately 1.7 months remaining)
- Negligible revenue generation ($2.5M) cannot offset operating losses; operating margin of -869% is unsustainable
- Imminent need for external financing will result in severe shareholder dilution; no insider buying activity in past 90 days suggests lack of confidence
- Pharmaceutical development is capital-intensive with extended timelines; no visibility into drug candidates or clinical trial success
- Severe operating losses and deeply negative free cash flow
- Short cash runway and high dilution/going-concern risk
- Execution and regulatory risk with volatile, non-recurring revenue sources
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway before financing necessity
- Revenue growth trajectory and pipeline advancement milestones
- Announcement of financing rounds and resulting dilution impact
- Quarterly operating cash burn and cash runway
- TTM revenue growth from partnerships/grants/licensing
GeoVax Labs, Inc. (GOVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.74x current ratio provides a solid financial cushion.
GOVX Profit Margin, ROE & Profitability Analysis
GOVX vs Healthcare Sector: How GeoVax Labs, Inc. Compares
How GeoVax Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GeoVax Labs, Inc. Stock Overvalued? GOVX Valuation Analysis 2026
Based on fundamental analysis, GeoVax Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GeoVax Labs, Inc. Balance Sheet: GOVX Debt, Cash & Liquidity
GOVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GeoVax Labs, Inc.'s revenue has grown significantly by 117% over the 5-year period, indicating strong business expansion. The most recent EPS of $-120.46 indicates the company is currently unprofitable.
GOVX Revenue Growth, EPS Growth & YoY Performance
GOVX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.1M | $-0.31 |
| Q2 2025 | $300.7K | -$5.1M | $-0.35 |
| Q1 2025 | N/A | -$5.4M | $-0.45 |
| Q3 2024 | N/A | -$4.0M | $-0.91 |
| Q2 2024 | N/A | -$4.0M | $-1.99 |
| Q3 2023 | N/A | -$2.2M | $-0.17 |
| Q2 2023 | N/A | -$2.2M | $-0.18 |
| Q1 2023 | N/A | -$2.4M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GeoVax Labs, Inc. Dividends, Buybacks & Capital Allocation
GOVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GeoVax Labs, Inc. (CIK: 0000832489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GOVX
What is the AI rating for GOVX?
GeoVax Labs, Inc. (GOVX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GOVX's key strengths?
Claude: Zero debt burden eliminates leverage risk. Positive stockholders equity of $3.8M remains on books. ChatGPT: Debt-free balance sheet. Solid current/quick ratio supporting near-term liquidity.
What are the risks of investing in GOVX?
Claude: Catastrophic cash burn of $21.5M annually against $3.1M cash runway (approximately 1.7 months remaining). Negligible revenue generation ($2.5M) cannot offset operating losses; operating margin of -869% is unsustainable. ChatGPT: Severe operating losses and deeply negative free cash flow. Short cash runway and high dilution/going-concern risk.
What is GOVX's revenue and growth?
GeoVax Labs, Inc. reported revenue of $2.5M.
Does GOVX pay dividends?
GeoVax Labs, Inc. does not currently pay dividends.
Where can I find GOVX SEC filings?
Official SEC filings for GeoVax Labs, Inc. (CIK: 0000832489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GOVX's EPS?
GeoVax Labs, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GOVX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GeoVax Labs, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GOVX stock overvalued or undervalued?
Valuation metrics for GOVX: ROE of -561.2% (sector avg: 15%), net margin of -862.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GOVX stock in 2026?
Our dual AI analysis gives GeoVax Labs, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GOVX's free cash flow?
GeoVax Labs, Inc.'s operating cash flow is $-21.5M, with capital expenditures of $27.6K. FCF margin is -863.8%.
How does GOVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -862.3% (avg: 12%), ROE -561.2% (avg: 15%), current ratio 2.74 (avg: 2).